Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
By D. Badesch, V. Tapson, M. McGoon, B. Brundage, L. Rubin, Fredrick Wigley, S. Rich, R. Barst, P. Barrett, K. Kral and 20 more. Annals of Internal Medicine, 2000
955 citations recorded by the source corpus.
Subfields: Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/03a9c652e4e05e20757a594a944ed76f896490fc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Pulmonary arterial hypertension (2013, background): “ment in functional capacity and hemodynamics in patients with PAH related to scleroderma-type diseases.(136) Despite”
- Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006, neutral): “Worsened by one class, n (%) 0 (0) 1 (3)”